Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $548,364.96 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 42,608 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $12.87, for a total value of $548,364.96. Following the transaction, the insider directly owned 899,877 shares in the company, valued at $11,581,416.99. This trade represents a 4.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

David Kirn also recently made the following trade(s):

• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $189,171.75.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Stock Performance

FDMT traded up $0.40 during trading on Tuesday, reaching $11.70. 651,784 shares of the stock were exchanged, compared to its average volume of 817,839. The stock’s 50 day moving average price is $10.26 and its two-hundred day moving average price is $9.36. 4D Molecular Therapeutics, Inc. has a twelve month low of $4.11 and a twelve month high of $14.00. The stock has a market cap of $611.68 million, a P/E ratio of -4.55 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. Equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of FDMT. RA Capital Management L.P. boosted its holdings in shares of 4D Molecular Therapeutics by 23.9% during the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after buying an additional 1,090,000 shares during the period. Janus Henderson Group PLC raised its holdings in 4D Molecular Therapeutics by 13.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after acquiring an additional 611,276 shares during the period. Goldman Sachs Group Inc. raised its holdings in 4D Molecular Therapeutics by 4.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after acquiring an additional 174,489 shares during the period. State Street Corp lifted its position in 4D Molecular Therapeutics by 197.5% during the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after acquiring an additional 1,785,106 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in 4D Molecular Therapeutics by 76.6% during the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock worth $14,520,000 after acquiring an additional 840,000 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on FDMT shares. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research report on Friday, May 8th. Chardan Capital reissued a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.